Douglas Hanahan

Ludwig Cancer Research — Switzerland

Medicine · Health Sciences

120h-index185.5kcitations395works30.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic function and diabetes(67), Neuroendocrine Tumor Research Advances(65), Pancreatic and Hepatic Oncology Research(47), Virus-based gene therapy research(43), Angiogenesis and VEGF in Cancer(35)

Publications394 total

Hallmarks of cancer—Then and now, and beyond
Cell·2026· 5 citedOpen Access
Figure S6 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Data from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S7 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S5 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Table S2 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Table S1 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S1 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S3 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S2 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
Figure S4 from HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
2025Open Access
HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
Cancer Discovery·2025· 2 citedOpen Access
A new effLuc/Kate dual reporter allele for tumor imaging in mice
Disease Models & Mechanisms·2025· 1 citedOpen Access
Abstract PR009: FMRP upregulation in cancer: Implicating FMRP-expressing cancer-associated fibroblasts in immune evasion
Cancer Research·2024
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Nature reviews. Cancer·2024· 58 citedOpen Access
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence
Cancer Cell·2024· 53 citedOpen Access
Milestones in tumor vascularization and its therapeutic targeting
Nature Cancer·2024· 49 citedOpen Access
Embracing cancer complexity: Hallmarks of systemic disease
Cell·2024· 384 citedOpen Access
Cancer Evolution: A Multifaceted Affair
Cancer Discovery·2023· 66 citedOpen Access
Supplemental Figure Legends from Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV<sup>+</sup> Cancers
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Gabriele Bergers(12), Lisa M. Coussens(4), Peter Olson(4), Judah Folkman(3), Joe W. Gray(3), Anguraj Sadanandam(3), Zena Werb(3), Morgan Truitt(3), Nicole Meyer-Morse(3), Emily K. Bergsland(3), Johanna A. Joyce(3), Enrico Giraudo(3), Robert A. Weinberg(2), Krisztián Homicskó(2), René Bernards(2), Thiennu H. Vu(2), Elizabeth Allen(2), Masahiro Inoue(2), Oriol Casanovas(2), Eric A. Collisson(2)